Non-cystic fibrosis bronchiectasis (NCFBE) is a rare, chronic lung disease characterized by bronchial inflammation and permanent airway dilation. Chronic infections with
P. aeruginosa have been linked to higher morbidity and mortality. To understand the impact of
P. aeruginosa in NCFBE on health care
[...] Read more.
Non-cystic fibrosis bronchiectasis (NCFBE) is a rare, chronic lung disease characterized by bronchial inflammation and permanent airway dilation. Chronic infections with
P. aeruginosa have been linked to higher morbidity and mortality. To understand the impact of
P. aeruginosa in NCFBE on health care costs and burden, we assessed healthcare costs and utilization before and after
P. aeruginosa diagnosis. Using data from 2007 to 2013 PharMetrics Plus administrative claims, we included patients with ≥2 claims for bronchiectasis and >1 claim for
P. aeruginosa; then excluded those with a claim for cystic fibrosis. Patients were indexed at first claim for
P. aeruginosa and were required to have >12 months before and after the index
P. aeruginosa. The mean differences in utilization and costs were assessed using paired Student’s
t-tests for statistical significance. Mean total healthcare costs per patient were $36,213 pre-
P. aeruginosa diagnosis versus $67,764 post-
P. aeruginosa, an increase of 87% (
p < 0.0001). Inpatient costs represented the largest proportion of total healthcare costs post-
P. aeruginosa (54%) with an increase of four hospitalizations per patient (
p < 0.0001). NCFBE patients with evidence of
P. aeruginosa incur substantially greater healthcare costs and utilization after
P. aeruginosa diagnosis. Future research should explore methods of earlier identification of NCFBE patients with
P. aeruginosa, as this may lead to fewer severe exacerbations, thereby resulting in a reduction in hospitalizations and healthcare costs.
Full article
